ライフサイエンスコーパス: triphosphate

1 tide substrates that are activated as the 5'-triphosphate.

2 tion of the template and incoming nucleoside triphosphate.

3 energy transfer molecules such as adenosine triphosphate.

4 NTPs into deoxyribonucleosides and inorganic triphosphate.

5 inding to guanosine diphosphate or guanosine triphosphate.

6 lated to become the pharmacologically active triphosphate.

7 helix-to engage the primer-template and dNTP triphosphate.

8 olysis of dNTPs into 2'-deoxynucleosides and triphosphate.

9 le of generating a broad range of nucleotide triphosphates.

10 sponding 3'-amino-2',3'-dideoxynucleoside 5'-triphosphates.

11 Despite widespread use, however, lamivudine triphosphate (3TC-TP) exposure in the FGT is unknown.

12 RT(Y115F/F116Y/Q151M):DNA complexed with 3TC-triphosphate (3TC-TP)/ETV-triphosphate (ETV-TP)/dCTP/dGT

13 5-methylcarboxyl-indolyl-2'-deoxyriboside 5'-triphosphate (5-MeCITP), functions as an inhibitor of te

14 his compound to the corresponding nucleoside triphosphate, 5-nitroindolyl-2'-deoxyriboside triphospha

15 on entails: increased synthesis of adenosine triphosphate, a reduced inflammatory response, increased

16 Extracellular adenosine triphosphate accelerated interleukin-12-driven IFN-gamma

17 ivation, as determined by assessing inositol triphosphate accumulation, intracellular calcium release

18 h bound AMPPNP (beta,gamma-imidoadenosine 5'-triphosphate, an ATP analog, resolution 3.1 angstrom), A

19 strates TMP and a non-hydrolyzable adenosine triphosphate analog, and in complex with a pair of produ

20 Nucleoside triphosphate analogues are presented, in which the gamma

21 haracterization of a new class of nucleoside triphosphate analogues comprising a C-alkyl-phosphonate

22 compounds formed gamma-C-(alkyl)-nucleoside triphosphate analogues with high selectivity because of

23 tabolized to 2'-fluoro-2'C-methylcytidine-5'-triphosphate and 2'-fluoro-2'C-methyluridine-5'-triphosp

24 n associated depletion of cellular guanosine triphosphate and adenosine triphosphate pools, and is co

25 yl terminus of the peptide through adenosine triphosphate and amino acyl-tRNA-dependent chemistry tha

26 icant increase in the synthesis of adenosine triphosphate and growth factors resulting in normalizati

27 ation is achieved mainly by constraining the triphosphate and guanine base positions while leaving th

28 of the primary energy currency, adenosine 5'-triphosphate and its use in the synthesis of biomolecule

29 gainst other metabolites (e.g., deoxyuridine triphosphate and l-2-hydroxyglutarate).

30 se cell-like compartments required adenosine triphosphate and microtubule polymerization but did not

31 ate cellular energy in the form of adenosine triphosphate and phosphocreatine (PCr).

32 Both Cdc42guanosine triphosphate and SNX9 activate N-WASP-WIP- and Arp2/3-me

33 Upon the addition of deoxynucleoside triphosphates and a polymerase, concatemers quickly form

34 and step-economical synthesis of nucleoside triphosphates and analogues on scale without the need fo

35 In vitro, HpRppH converts RNA 5'-triphosphates and diphosphates to monophosphates.

36 imports the constituent unnatural nucleoside triphosphates and uses them to replicate DNA containing

37 including toxin-antitoxin modules, adenosine triphosphate, and guanosine (penta) tetraphosphate, resp

38 ons, covariation of magnesium and nucleoside triphosphates, and the effects of several typical additi

39 oved potency in a guanosine 5'-O-[gamma-thio]triphosphate assay, exhibited metabolic stability, and l

40 sites of RFC are fully bound to adenosine 5'-triphosphate (ATP) analogs, which is expected to induce

41 primates have a >70% reduction in adenosine triphosphate (ATP) and a decrease in cytochrome c oxidas

42 organic tripolyphosphate (3polyP), adenosine triphosphate (ATP) and adenosine monophosphate supported

43 protein-coupled receptor agonists adenosine triphosphate (ATP) and histamine promoted rapid increase

44 ter from Aquifex aeolicus bound to adenosine triphosphate (ATP) and in a lipid environment, revealing

45 Measurements of adenosine triphosphate (ATP) and metabarcoding of environmental nu

46 we employed sequences specific for adenosine triphosphate (ATP) and tobramycin as test-bed targets be

47 letonema costatum, in utilizing adenosine-5'-triphosphate (ATP) based on incubation experiments under

48 They utilize cycles of adenosine triphosphate (ATP) binding and hydrolysis to transport t

49 ngle about 40 degrees after the adenosine 5'-triphosphate (ATP) binding dwell.

50 "alkyl-induced" pockets within the adenosine triphosphate (ATP) binding site of PI3Kgamma.

51 estigate the impact of variants on adenosine triphosphate (ATP) binding.

52 g SPR detection compared to the adenosine 5'-triphosphate (ATP) bioluminescence assay in microtiter p

53 hortening because of hydrolysis of adenosine triphosphate (ATP) by myosin molecular motors.

54 hanges in membrane potential or adenosine 5'-triphosphate (ATP) concentration result from AapA1 expre

55 Only under cellular adenosine triphosphate (ATP) concentrations, these changes cumulat

56 We assessed the adenosine triphosphate (ATP) content decay of mouse liver grafts a

57 CofB also shows activation by adenosine triphosphate (ATP) despite the reaction requiring neithe

58 yotic DNA ligases are known to use adenosine triphosphate (ATP) for DNA ligation.

59 genomes is essential for efficient adenosine triphosphate (ATP) generation.

60 DNA compaction by cohesin requires adenosine triphosphate (ATP) hydrolysis and is force sensitive.

61 f stimulation of P-glycoprotein adenosine 5'-triphosphate (ATP) hydrolysis by multiple substrates and

62 fusion numerical simulations of 1) adenosine triphosphate (ATP) hydrolysis into adenosine monophospha

63 DEAH helicases couple adenosine triphosphate (ATP) hydrolysis to conformational changes

64 nsemble measurements, Mot1 can use adenosine triphosphate (ATP) hydrolysis to displace TBP from DNA a

65 protein) increased proteasomal adenosine 5'-triphosphate (ATP) hydrolysis, the step which commits su

66 lso dramatically stimulates the adenosine 5'-triphosphate (ATP) hydrolysis-driven motor activity of D

67 ciliary and flagellar beating via adenosine triphosphate (ATP) hydrolysis.

68 Adenosine 5' triphosphate (ATP) is a universal intracellular energy s

69 ked adjacent to myofibrils because adenosine triphosphate (ATP) is needed to fuel sarcomere shortenin

70 In tissue infections, adenosine triphosphate (ATP) is released into extracellular space

71 Adenosine triphosphate (ATP) is released into the extracellular en

72 tochondrial fragmentation, reduced adenosine triphosphate (ATP) levels and a higher fatigability at t

73 unctionality with reduced cellular adenosine triphosphate (ATP) levels, altered mitochondrial morphol

74 ackward steps and the number of adenosine 5'-triphosphate (ATP) molecules hydrolyzed per step is demo

75 ed calcium levels, and also higher adenosine triphosphate (ATP) production capacity than those isolat

76 ge of cellular functions including adenosine triphosphate (ATP) production, lipid synthesis, and prot

77 iron-sulfur cluster biogenesis and adenosine triphosphate (ATP) production.

78 Adenosine triphosphate (ATP) promoted the reaction but was not ess

79 The plasma membrane adenosine triphosphate (ATP) release channel pannexin 1 (PANX1) ha

80 mall molecules, with comparable adenosine 5'-triphosphate (ATP) rescue activity to idebenone.

81 f the F(1)-catalytic domain of the adenosine triphosphate (ATP) synthase has been determined from Myc

82 The adenosine triphosphate (ATP) synthase in human mitochondria is a m

83 : Mitochondrial O2 consumption and adenosine triphosphate (ATP) synthesis rates of osteosarcoma cybri

84 cin, an inhibitor of mitochondrial adenosine triphosphate (ATP) synthesis.

85 monstrated that in the presence of adenosine triphosphate (ATP) the human RAD51 (HsRAD51) recombinase

86 in cell systems, administration of adenosine triphosphate (ATP) to mice enhanced lipopolysaccharide (

87 se fold transfer phosphate from adenosine 5'-triphosphate (ATP) to substrates in a process known as p

88 ssed or infected cells can release adenosine triphosphate (ATP) to the extracellular medium, which ca

89 h P(i) liberation in real-time for adenosine triphosphate (ATP) turnover by myosin, the actomyosin sy

90 ect the low weight target molecule adenosine triphosphate (ATP), a common biomarker, which plays an i

91 CA) intermediates and synthesis of adenosine triphosphate (ATP), but the reason for glutamate excreti

92 tochondria, an important source of adenosine triphosphate (ATP), has been the subject of much researc

93 lecules including small molecules (adenosine triphosphate (ATP), limit of detection (LOD) of 0.1 nM),

94 with lipopolysaccharide (LPS) and adenosine triphosphate (ATP), or 4OH-tamoxifen, respectively.

95 utilize the excessive presence of adenosine triphosphate (ATP), riboflavin, and Zn(2+) in tumors.

96 t al. describe novel effects of adenosine 5'-triphosphate (ATP), which is secreted by keratinocytes a

97 ABCB4 (MDR3) is an adenosine triphosphate (ATP)-binding cassette (ABC) transporter ex

98 We focused on adenosine triphosphate (ATP)-binding cassette (ABC) transporters i

99 n adenosine diphosphate (ADP)- and adenosine triphosphate (ATP)-bound conformations, highlighting dif

100 sions in rat molars shows that the adenosine triphosphate (ATP)-competitive GSK-3 inhibitor, CHIR9902

101 While many different classes of adenosine 5'-triphosphate (ATP)-competitive inhibitors have been desc

102 be HSP70 family chaperones, whose adenosine triphosphate (ATP)-dependent activity maintained the liq

103 We show that Uls1, an adenosine triphosphate (ATP)-dependent chromatin remodelling (Snf2

104 nl) exemplifies the Rnl5 family of adenosine triphosphate (ATP)-dependent polynucleotide ligases that

105 First, we build an adenosine triphosphate (ATP)-driven DNA nanogatekeeper.

106 ific protein substrates before the adenosine triphosphate (ATP)-fueled mechanical unfolding and trans

107 nesis supports a model in which adenosine 5'-triphosphate (ATP)-powered movements of the H2I are tran

108 cationic porphyrin that undergoes adenosine triphosphate (ATP)-templated self-assembly into right-ha

109 orm the biological energy currency adenosine triphosphate (ATP).

110 drolysis of fuel molecules such as adenosine triphosphate (ATP).

111 a-rotation angle dependence of the adenosine triphosphate (ATP)/adenosine diphosphate (ADP) exchange

112 doreduction coenzymes, purine ribonucleoside triphosphate, ATP and propanoate, which are considered a

113 yzable ATP analog, adenosine 5'-(gamma-thio)-triphosphate (ATPgammaS) added intravenously (i.v.).

114 specificity profiles for rat P2X2 receptors; triphosphate-bearing analogues display broad activity, t

115 naling events such as guanosine 5'-3-O-(thio)triphosphate binding and beta-arrestin2 recruitment.

116 ar motors to couple the energy of nucleoside triphosphate binding and hydrolysis to mechanical moveme

117 [SLC10A2]) and six known loci (in adenosine triphosphate binding cassette subfamily G member 8 [ABCG

118 d III inhibitors at or near the adenosine 5'-triphosphate binding sites are well defined, the literat

119 or nucleoside selection, metal coordination, triphosphate binding, and RNA template stabilization.

120 r binding and [(35)S] guanosine 5'-3-O-(thio)triphosphate binding.

121 g resistance-associated protein 1 (adenosine triphosphate-binding cassette subfamily C member 1 [ABCC

122 The adenosine triphosphate-binding cassette transporters P-glycoprotei

123 rio, led to increased abundance of guanosine triphosphate-bound RhoA (RhoA.GTP) in human cells.

124 how that the bioactive metabolite decitabine triphosphate, but not azacytidine triphosphate, function

125 with 2'(3')-O-(4-Benzoylbenzoyl)adenosine 5'-triphosphate (BzATP).

126 ome studies are bempedoic acid, an adenosine triphosphate-citrate lyase inhibitor that reduces choles

127 s, including the requirement for a guanosine triphosphate cofactor and the generation of long stagger

128 itionally, we infer that the bound guanosine triphosphate cofactor interacts with the terminal base o

129 in targeting cancers resistant to adenosine triphosphate competitive drugs.

130 tochondrial membrane potential, adenosine 5'-triphosphate contents, and reactive oxygen species level

131 nophosphate (IMP) dehydrogenase and cytosine triphosphate (CTP) synthase.

132 rated to catalyze the conversion of cytidine triphosphate (CTP) to 3'-deoxy-3',4'-didehydro-CTP (ddhC

133 ly occurring nucleotide 2-deoxy-adenosine 5'-triphosphate (dATP) can be used by cardiac muscle as an

134 nhance the intrinsic levels of deoxycytidine triphosphate (dCTP).

135 may be generated by extracellular adenosine triphosphate degradation, impairs the parenchymal CD4+ T

136 l-regulated kinase 1/2, determining inositol triphosphate-dependent Ca2+ release from the endoplasmic

137 Adenosine 5'-triphosphate-dependent closure of the Prp28 RecA domains

138 f a replication error it undergoes adenosine triphosphate-dependent conformational changes and recrui

139 vel therapeutic strategy to dampen adenosine triphosphate-dependent IL-1beta signaling.

140 zation to succinyl-ZMP, ZDP, or ZTP (di- and triphosphate derivatives of AICAR) strongly reduced its

141 hydroxide results in ring opening to linear triphosphate derivatives.

142 tion then led to the use of the more complex triphosphate derivatives.

143 by ectonucleotidases such as ectonucleoside triphosphate diphosphohydrolase 1 (CD39) and 5'-nucleoti

144 Ectonucleoside triphosphate diphosphohydrolase 1 (NTPDase1) degrades th

145 Nucleoside 5'-triphosphate (dNTP) analogues in which the beta,gamma-ox

146 HD1 regulates cellular 2'-deoxynucleoside-5'-triphosphate (dNTP) homeostasis by catalysing the hydrol

147 g cells, likely due to lower deoxynucleoside triphosphate (dNTP) levels and the presence of multiple

148 antification of cellular deoxyribonucleoside triphosphate (dNTP) levels is important for studying pat

149 crescentus Lon controls deoxyribonucleoside triphosphate (dNTP) pools during stress through degradat

150 cing platform that uses step-wise nucleotide triphosphate (dNTP) release, capture and detection in mi

151 SAMHD1 is a deoxynucleoside triphosphate (dNTP) triphosphohydrolase that cleaves phy

152 2'-Deoxynucleoside 5'-(alpha-P-seleno)-triphosphates (dNTPalphaSe) have been conveniently synth

153 ad range of natural and unnatural nucleoside triphosphates (dNTPs and xNTPs) using protocols that are

154 zyme in the synthesis of deoxyribonucleoside triphosphates (dNTPs) and essential for both DNA replica

155 ta) can incorporate both deoxyribonucleoside triphosphates (dNTPs) and ribonucleoside triphosphates (

156 of de novo synthesis of deoxyribonucleotide triphosphates (dNTPs) building blocks for DNA synthesis,

157 e in the biosynthesis of deoxyribonucleoside triphosphates (dNTPs) that are essential for DNA replica

158 that degrades intracellular deoxynucleoside triphosphates (dNTPs) to a lower level that restricts vi

159 e HIV-1 life cycle, requires deoxynucleotide triphosphates (dNTPs) to fuel DNA synthesis, thus requir

160 uch higher than those of deoxyribonucleoside triphosphates (dNTPs), thereby influencing the frequency

161 letion of otherwise essential deoxythymidine triphosphate (dTTP)-producing pathways and shields them

162 Sensing of extracellular adenosine triphosphate (eATP) by the purinergic receptor P2RX7 is

163 complexed with 3TC-triphosphate (3TC-TP)/ETV-triphosphate (ETV-TP)/dCTP/dGTP.

164 reclinical studies, intracellular islatravir-triphosphate exhibits a long half-life and prolonged vir

165 eta) selects the correct deoxyribonucleoside triphosphate for incorporation into the DNA polymer.

166 ously shown that incorporation of the active triphosphate form of RDV (RDV-TP) at position i causes d

167 his RdRp efficiently incorporates the active triphosphate form of RDV (RDV-TP) into RNA.

168 The triphosphate form of the inhibitor (RDV-TP) competes wit

169 When Fapy*dG is in its nucleotide triphosphate form, Fapy*dGTP, it is inefficiently cleans

170 The 5'-triphosphate formed from these phosphoramidates selectiv

171 In this regard, the triphosphate forms of 2'-C-methylated compounds, includi

172 liver facilitating the release of adenosine triphosphate from hepatocytes.

173 fovir diphosphate (TFV-DP) and emtricitabine triphosphate (FTC-TP) in the FGT have been previously de

174 decitabine triphosphate, but not azacytidine triphosphate, functions as activator and substrate of th

175 The P2X7 receptor (P2X7R) is an adenosine triphosphate-gated ion channel that is predominantly exp

176 The P2X7 receptor is an adenosine triphosphate-gated ion channel, which is abundantly expr

177 ted rates of mineral oxidation and adenosine triphosphate generation relative to sterile diorite susp

178 le maintenance due to its role in nucleotide triphosphate generation.

179 Guanosine triphosphate (GTP) cyclohydrolase I (GCH1) catalyzes the

180 kinase (RTK) ligands increase RhoA-guanosine triphosphate (GTP) in untransformed and transformed cell

181 or complexes that depends on a Ran-guanosine triphosphate (GTP) signal [12], which is sufficient to d

182 Guanosine triphosphate (GTP) turnover, guanosine diphosphate relea

183 ed intrinsic rate of hydrolysis of guanosine triphosphate (GTP), which results in their accumulation

184 Septins (SEPTs) are filamentous guanosine-5'-triphosphate (GTP)-binding proteins, which affect microt

185 isplayed characteristics of active guanosine triphosphate (GTP)-bound RAC2 including enhanced superox

186 and deactivated for assembly by a guanosine triphosphate (GTP)-driven reaction cycle, and the emergi

187 1) for binding to guanosine 5'-O-[gamma-thio]triphosphate (GTPgammaS)-stabilized MTs, which mimic the

188 es the conversion of GTP to dihydroneopterin triphosphate (H2NTP), the initiating step in the biosynt

189 bled, as by Sec17, Sec18, and ATP (adenosine triphosphate), HOPS is required, and GST-PX does not suf

190 Targeting nucleoside triphosphate hydrolase activity (CD39) toward activated

191 conditions of sepsis, agents with nucleoside triphosphate hydrolase activity decreased platelet-leuko

192 oach was evaluated, which targets nucleoside triphosphate hydrolase activity toward activated platele

193 al of activated platelet targeted nucleoside triphosphate hydrolase activity, we employed a potato ap

194 enriched in the P-loop containing nucleoside triphosphate hydrolases domain (P-loop).

195 reover, the IDRs also regulate the adenosine triphosphate hydrolysis and nuclease activities that are

196 ctin (dis-)assembly, and catalytic guanosine triphosphate hydrolysis is found in tubulin (dis-)assemb

197 s two distinct folds, and the post-adenosine triphosphate hydrolysis state of KaiC create a hub aroun

198 hat couple the chemical energy of nucleoside triphosphate hydrolysis to the mechanical functions requ

199 ial flagellar motor (BFM), ATP (adenosine-5'-triphosphate) hydrolysis probably drives both motor rota

200 site controls the dynamics of the adenosine triphosphate-hydrolyzing NBDs.

201 otide) and tissues (eg, succinate, adenosine triphosphate, hypoxia-inducible factor-1alpha, nuclear f

202 Natural and modified nucleoside triphosphates impact nearly every major aspect of health

203 associated with greater amounts of adenoside triphosphate in the cortex HMP/O2 versus HMP/Air kidneys

204 Intratracheal replenishment of adenosine triphosphate in Trpv4 mice abrogated the protective effe

205 nversion of 3'-deoxyinosine to cordycepin 5'-triphosphate in vitro using macrophage-like RAW264.7 cel

206 riphosphate, 5-nitroindolyl-2'-deoxyriboside triphosphate, in vivo creates a potent inhibitor of seve

207 (sGC) catalyzes the conversion of guanosine triphosphate into cyclic guanosine-3',5'-monophosphate,

208 n the gamma and beta phosphates of adenosine triphosphate into mechanical work, which results in the

209 that in vitro, YvcI converts RNA 5'-di- and triphosphates into monophosphates in the presence of man

210 The islatravir-triphosphate intracellular half-life was 78.5-128.0 h.

211 tcomes were islatravir plasma and islatravir-triphosphate intracellular pharmacokinetics.

212 aling system consisting of PLCbeta, inositol triphosphate (IP(3)), IP(3) receptors, and Ryanodine rec

213 We subsequently demonstrated that Sofosbuvir triphosphate is incorporated by the relatively low fidel

214 Transphosphorylation of nucleotide triphosphates is the central reaction in DNA replication

215 hanism of transphosphorylation of nucleotide triphosphates is, in most cases, unknown.

216 The final byproduct of the reaction, triphosphate, is shown to be less inhibitory to primer e

217 pH value, conductivity/impedance, adenosine triphosphate level, concentration of dissolved oxygen an

218 eased intracellular charge, higher adenosine triphosphate level, quicker substrate consumption and mo

219 Increased intracellular adenosine triphosphate levels activate the purinergic receptor P2R

220 oup exhibited significantly higher adenosine triphosphate levels and lower expression of phosphorylat

221 Panx3 by modulating intracellular adenosine triphosphate levels and thereby enhanced HaCaT cell migr

222 carboxylic acid cycle activity and adenosine triphosphate levels as a consequence of enhanced IDH2 en

223 Adenosine triphosphate levels significantly improved during HMP wh

224 Adenosine triphosphate levels under UW preservation fall to less t

225 ic drop in glycolysis and cellular adenosine triphosphate levels while oxidative phosphorylation is m

226 did not increase phosphatidylinositol 3,4,5-triphosphate levels.

227 Ras but increased phosphatidylinositol 3,4,5-triphosphate levels.

228 of HMP, with reciprocal changes in adenoside triphosphate levels.

229 f action may be related to altered guanosine triphosphate loading.

230 different targets: the N6-methyladenosine-5'-triphosphate (m6ATP) ribonucleotide, a short synthetic R

231 e substrate analog 2',3'-dideoxyguanosine-5'-triphosphate, MnCl2, and tartrate, but their quaternary

232 the tunnel entry, and interactions with the triphosphate moiety orient it such that its base moiety

233 ynucleotidyl transferase 2'-Deoxyuridine, 5'-Triphosphate nick end labeling and p65 staining was used

234 ucleotidyl transferase mediated deoxyuridine triphosphate nick end labeling assay.

235 ynucleotidyl transferase 2'-deoxyuridine, 5'-triphosphate nick end labeling staining versus kidneys t

236 y employing a small library of nucleotide-5'-triphosphate (NTP) analogues and use them to prepare 33

237 We disclose a study on nucleoside triphosphate (NTP) analogues in which the gamma-phosphat

238 We developed a nucleoside triphosphate (NTP) delivery system (the TriPPPro approac

239 Elevated dNTP/nucleotide triphosphate (NTP) ratios in Deltalon cells protects the

240 synthesize complex RNAs using nucleoside 5'-triphosphate (NTP) substrates.

241 ultimately the bioactive nucleoside analogue triphosphates (NTP).

242 of RNA and DNA polymerases for nucleoside-5'-triphosphates (NTPs) could help define the catalytic mec

243 1-100 residues and adenosine mono-, di-, and triphosphate nucleotides are used as model polyions.

244 The triphosphate of analog A5 was specifically incorporated

245 at the viperin substrate may be a nucleoside triphosphate of some type.

246 e interface with the primer-template and the triphosphate of the incoming dNTP.

247 onversion of nucleoside analogues into their triphosphates often proceeds insufficiently.

248 that liposomes containing calcium, adenosine triphosphate, or carboxyfluorescein are tethered to plas

249 fic inhibitors targeting the TRPV4/adenosine triphosphate/P2X signaling axis, may represent a novel s

250 harmacokinetics and intracellular islatravir-triphosphate pharmacokinetics were approximately dose pr

251 lin signaling via phosphatidylinositol 3,4,5-triphosphate (PIP(3)).

252 l enrichment of phosphatidylinositol (3,4,5)-triphosphate (PIP3) within the spine plasma membrane.

253 tive oxygen species (ROS) oxidize nucleotide triphosphate pools (e.g., 8-oxodGTP), which may kill cel

254 ellular guanosine triphosphate and adenosine triphosphate pools, and is counteracted by its HD domain

255 e model of lipopolysaccharide plus adenosine triphosphate, PRL inhibited the priming (expression of I

256 /ERK pathway (phospholipase C/inositol 1,4,5-triphosphate/protein kinase C/extracellular signal-regul

257 d by karyopherins (Kaps) and a Ran guanosine triphosphate (RanGTP) gradient that imports nuclear loca

258 ort NLS-NCs through NPCs while Ran guanosine triphosphate (RanGTP) promotes their release from NPCs i

259 r ryanodine receptor (RyR) or inositol 1,4,5-triphosphate receptor (IP(3)R) dysfunction in the pathop

260 ediated Ca2+ oscillations and inositol 1,4,5-triphosphate receptor (IP3R)-induced cytosolic signals i

261 conjunction with stimulation of the inositol triphosphate receptor (IP3R).

262 are mediated by stimulation of the inositol triphosphate receptor 1 (INSP3R1).

263 um-mediated signaling through inositol 1,4,5-triphosphate receptors (IP(3)Rs) is essential for the re

264 that the absence of ABCC6-mediated adenosine triphosphate release from the liver and, consequently, r

265 phosphate and 2'-fluoro-2'C-methyluridine-5'-triphosphate, respectively.

266 ults reveal the importance of controlling 5'-triphosphate RNA levels to prevent aberrant RIG-I signal

267 Reducing DUSP11 levels alters host triphosphate RNA packaged in extracellular vesicles and

268 SP11) acts on both host and virus-derived 5'-triphosphate RNAs rendering them less active in inducing

269 ide triphosphates (dNTPs) and ribonucleoside triphosphates (rNTPs) and can use both DNA and RNA as su

270 Cellular levels of ribonucleoside triphosphates (rNTPs) are much higher than those of deox

271 NA polymerases misincorporate ribonucleoside triphosphates (rNTPs) into DNA approximately once every

272 hosp27) to CDK4 altered the kinase adenosine triphosphate site to promote phosphorylation of the reti

273 to the discovery of a drug-like adenosine 5'-triphosphate-site PI3K/mTOR kinase inhibitor: (S)-4-(dif

274 o be highly active against modified cytidine triphosphates, such as 5-methyl-dCTP, which, if incorrec

275 he intrinsic capacity to hydrolyze guanosine triphosphate, suggesting that the mechanism of action ma

276 blocked proliferation by limiting nucleotide triphosphate synthesis.

277 pEF were enriched in mitochondrial adenosine triphosphate synthesis/electron transport, pathways down

278 ork, we synthesized an artificial nucleotide triphosphate that is selectively inserted opposite O(6)-

279 It demonstrated that cordycepin 5'-triphosphate, the active metabolite of cordycepin, can b

280 and activated sGC enzyme converts guanosine triphosphate to an important second messenger cGMP.

281 es the intracellular conversion of guanosine triphosphate to cGMP (cyclic 3',5'-guanosine monophospha

282 rmational change of EF-Tu from the guanosine triphosphate to guanine diphosphate conformation during

283 livery of a stable gamma-modified nucleoside triphosphate to increase the selectivity of such compoun

284 ATPase (enzymatic hydrolysis of adenosine triphosphate to inorganic phosphate) levels were measure

285 tral role in energetics, producing adenosine triphosphate to power most cellular processes.

286 lectivity of these gamma-modified nucleoside triphosphates to act as substrates for HIV-RT, while the

287 bules elongate by addition of bent guanosine triphosphate tubulin to the tips of curving protofilamen

288 s is crucial for the regulation of adenosine triphosphate turnover in the first nucleotide-binding do

289 eno-fused 7-deazaadenine derivative, and the triphosphate was a good substrate for KOD XL DNA polymer

290 The 8-TrzdA 5'-triphosphate was incorporated into duplex DNA containing

291 ferrocenylethynyl)-7-deaza-2'-deoxyadenosine triphosphate was optimised in terms of a compromise betw

292 as demonstrated in four prawn samples, while triphosphate was quantified (11.2 +/- 4 ug/g) in another

293 Adenosine triphosphate was selected as the target life marker.

294 rodrugs of these gamma-ketobenzyl nucleoside triphosphates was prepared.

295 three isomers of a synthetic non-nucleoside triphosphate, we demonstrate that myosin's force- and mo

296 2'-Deoxyribonucleoside and its 5'-O-triphosphate were also prepared from benzothieno-fused 7

297 In vitro, 2'-F-nucleoside 5'-triphosphates were neither inhibitors nor preferred subs

298 Moreover, the corresponding 5' triphosphates were not substrates for mitochondrial DNA

299 Six 1',5'-anhydrohexitol uridine triphosphates were synthesized with aromatic substitutio

300 zole-4-carboxamide-1-beta-D-ribofuranosyl 5'-triphosphate (ZTP), activate the response regulator UvrY